Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Petr Novak (109770)
Reinhold Schmidt (33935)
Eva Kontsekova (5894363)
Branislav Kovacech (5894366)
Tomas Smolek (5894369)
Stanislav Katina (849475)
Lubica Fialova (5894372)
Michal Prcina (5894375)
Vojtech Parrak (5894378)
Peter Dal-Bianco (292140)
Martin Brunner (805199)
Wolfgang Staffen (5894381)
Michael Rainer (5894384)
Matej Ondrus (5894387)
Stefan Ropele (310902)
Miroslav Smisek (5894390)
Roman Sivak (5894393)
Norbert Zilka (5894396)
Bengt Winblad (281202)
Michal Novak (3945095)

Publication date

October 2018

DOI

10.6084/m9.figshare.7251116.v1

Abstract

Supplementary material for FUNDAMANT: An interventional 72-week phase 1 follow study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease. (DOCX 4564 kb

Extracted data

We use cookies to provide a better user experience.

Data Protection

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Petr Novak (109770)
Reinhold Schmidt (33935)
Eva Kontsekova (5894363)
Branislav Kovacech (5894366)
Tomas Smolek (5894369)
Stanislav Katina (849475)
Lubica Fialova (5894372)
Michal Prcina (5894375)
Vojtech Parrak (5894378)
Peter Dal-Bianco (292140)
Martin Brunner (805199)
Wolfgang Staffen (5894381)
Michael Rainer (5894384)
Matej Ondrus (5894387)
Stefan Ropele (310902)
Miroslav Smisek (5894390)
Roman Sivak (5894393)
Norbert Zilka (5894396)
Bengt Winblad (281202)
Michal Novak (3945095)

Open link

Publication date

October 2018

DOI

10.6084/m9.figshare.7251116.v1

Abstract

Supplementary material for FUNDAMANT: An interventional 72-week phase 1 follow study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease. (DOCX 4564 kb

Extracted data

Steinunn Thordardottir (5205731)
Elena Rodriguez-Vieitez (5205734)
Ove Almkvist (3463091)
Daniel Ferreira (4515394)
Laure Saint-Aubert (3463088)
Anne Kinhult-Ståhlbom (5205737)
Håkan Thonberg (6730)
Michael Schöll (4742400)
Eric Westman (24165)
Anders Wall (3115698)
Maria Eriksdotter (693854)
Henrik Zetterberg (144718)
Kaj Blennow (58615)
Agneta Nordberg (234998)
Caroline Graff (281203)

May 2018

Longitudinal z-scores for the RAVL total learning test measuring episodic memory in brothers A and B...

Additional file 1: of First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimerâs disease

Marielle Delnomdedieu (434291)
Sridhar Duvvuri (3491186)
David Li (194538)
Nazem Atassi (3491174)
Ming Lu (122276)
H. Brashear (3429248)
Enchi Liu (3491183)
Seth Ness (3491177)
James Kupiec (3491180)

March 2016

List of investigators and corresponding ethics committees or institutional review boards. (DOC 60 kb

Additional file 1: of Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression?

Paola Italiani (519267)
Ilaria Puxeddu (303574)
Sabrina Napoletano (6081056)
Emanuele Scala (6081059)
Daniela Melillo (545973)
Simone Manocchio (6081062)
Antonella Angiolillo (2795587)
Paola Migliorini (361490)
Diana Boraschi (5088)
Emilia Vitale (271466)
Alfonso Costanzo (6081065)

December 2018

Results of multiple linear regression models without control for confounding variables. Values are β...

Additional file 1: of Systemic infection modifies the neuroinflammatory response in late stage Alzheimer’s disease

Sonja Rakic (5729885)
Yat Hung (5729888)
Matthew Smith (326340)
Denise So (5729891)
Hannah Tayler (5729894)
William Varney (5729897)
Joe Wild (5729900)
Scott Harris (306518)
Clive Holmes (237359)
Seth Love (122101)
William Stewart (28871)
James Nicoll (4733223)
Delphine Boche (458992)

September 2018

Table S1. Characteristics of the primary antibodies, immunohistochemistry conditions and expression ...

Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâs disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Femminella (6553430)
Eleni Frangou (6553433)
Sharon Love (6245381)
Gail Busza (6553436)
Clive Holmes (237359)
Craig Ritchie (3531092)
Robert Lawrence (229647)
Brady McFarlane (6553439)
George Tadros (6553442)
Basil Ridha (6553445)
Carol Bannister (6553448)
Zuzana Walker (573075)
Hilary Archer (6553451)
Elizabeth Coulthard (6553454)
Ben Underwood (6553457)
Aparna Prasanna (6553460)
Paul Koranteng (6553463)
Salman Karim (6553466)
Kehinde Junaid (6553469)
Bernadette McGuinness (237354)
Ramin Nilforooshan (5172128)
Ajay Macharouthu (6553472)
Andrew Donaldson (6553475)
Simon Thacker (6553478)
Gregor Russell (6553481)
Naghma Malik (6553484)
Vandana Mate (6553487)
Lucy Knight (6553490)
Sajeev Kshemendran (6553493)
John Harrison (3512513)
David Brooks (5369636)
Anthony Passmore (6553496)
Clive Ballard (89605)
Paul Edison (6398009)

April 2019

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb

Additional file 1 of Therapeutic non-invasive brain treatments in Alzheimer’s disease: recent advances and challenges

Chongyun Wu (13895282)
Luoman Yang (13895285)
Shu Feng (391684)
Ling Zhu (56356)
Luodan Yang (13895288)
Timon Cheng-Yi Liu (13895291)
Rui Duan (561668)

October 2022

Additional file 1: Supplementary Table 1. Non-invasive Therapies in Clinical Trials

Additional file 2: of Detection of tau in Gerstmann-StrĂ¤ussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET

Shannon Risacher (3578255)
Martin Farlow (229715)
Daniel Bateman (5907221)
Francine Epperson (5907224)
Eileen Tallman (5907227)
Rose Richardson (4102288)
Jill Murrell (281856)
Frederick Unverzagt (4837701)
Liana Apostolova (5907230)
Jose Bonnin (5907233)
Bernardino Ghetti (229719)
Andrew Saykin (3203685)

October 2018

Table S1. Regional [18F]Flortaucipir SUVR in PRNP F198S GSS Patients Relative to Early-Onset Alzheim...

Additional file 1: of Reducing disability via a family centered intervention for acutely ill persons with Alzheimerâs disease and related dementias: protocol of a cluster-randomized controlled trial (Fam-FFC study)

Marie Boltz (5755031)
Ashley Kuzmik (5755034)
Barbara Resnick (5755037)
Rebecca Trotta (5755043)
Jacqueline Mogle (5755046)
Rhonda BeLue (4962424)
Douglas Leslie (5755049)
James Galvin (5755052)

September 2018

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist. (PDF 175...

Additional file 1: of Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimerâs disease: a network meta-analysis of 41 randomized controlled trials

Kai-Xin Dou (6161522)
Meng-Shan Tan (6161525)
Chen-Chen Tan (523854)
Xi-Peng Cao (5206148)
Xiao-He Hou (6161528)
Qi-Hao Guo (6161531)
Lan Tan (477054)
Vincent Mok (397930)
Jin-Tai Yu (477053)

December 2018

Supplementary 1. Network meta-analysis model. Supplementary 2. References for included trials. Suppl...

Additional file 1: of Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease

Hua Zhang (12549)
Kok Ng (5799602)
Joseph Therriault (5799605)
Min Kang (287002)
Tharick Pascoal (3581390)
Pedro Rosa-Neto (301841)
Serge Gauthier (301840)

September 2018

Table S1. Diagnostic accuracy of CSF P-tau, VILIP-1, and YKL-40 (Adjusted for age, gender, education...

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease in two global, randomized, phase 3 trials

Rik Vandenberghe (674079)
Juha Rinne (3429236)
MercĂ¨ Boada (3429254)
Sadao Katayama (3429221)
Philip Scheltens (142045)
Bruno Vellas (133953)
Michael Tuchman (3429227)
Achim Gass (539278)
Jochen Fiebach (3429218)
Derek Hill (3429203)
Kasia Lobello (3429245)
David Li (194538)
Tom McRae (3429230)
Prisca Lucas (3429212)
Iona Evans (3429239)
Kevin Booth (3429224)
Gerald Luscan (3429209)
Bradley Wyman (3429233)
Lisa Hua (3429251)
Lingfeng Yang (3429206)
H. Brashear (3429248)
Ronald Black (3429215)

May 2016

Inclusion and exclusion criteria. Inclusion and exclusion criteria, similar to those used in the 301...

Additional file 2: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S1. SUVR longitudinal analysis. SUVR at week 69 compared to SUVR at baseline using different ...

Additional file 1: of Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Antonella Tramutola (284818)
Chiara Lanzillotta (5933198)
Eugenio Barone (297203)
Andrea Arena (5933201)
Ilaria Zuliani (5933204)
Luciana Mosca (83281)
Carla Blarzino (328306)
D. Butterfield (5933210)
Marzia Perluigi (297205)
Fabio Di Domenico (328312)

November 2018

List of antibodies used for WB and IF analysis. For each antibody employed in the study is reported ...

Additional file 1: of Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

Steinunn Thordardottir (5205731)
Elena Rodriguez-Vieitez (5205734)
Ove Almkvist (3463091)
Daniel Ferreira (4515394)
Laure Saint-Aubert (3463088)
Anne Kinhult-Ståhlbom (5205737)
Håkan Thonberg (6730)
Michael Schöll (4742400)
Eric Westman (24165)
Anders Wall (3115698)
Maria Eriksdotter (693854)
Henrik Zetterberg (144718)
Kaj Blennow (58615)
Agneta Nordberg (234998)
Caroline Graff (281203)

May 2018

Longitudinal z-scores for the RAVL total learning test measuring episodic memory in brothers A and B...

Marielle Delnomdedieu (434291)
Sridhar Duvvuri (3491186)
David Li (194538)
Nazem Atassi (3491174)
Ming Lu (122276)
H. Brashear (3429248)
Enchi Liu (3491183)
Seth Ness (3491177)
James Kupiec (3491180)

March 2016

List of investigators and corresponding ethics committees or institutional review boards. (DOC 60 kb

Additional file 1: of Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression?

Paola Italiani (519267)
Ilaria Puxeddu (303574)
Sabrina Napoletano (6081056)
Emanuele Scala (6081059)
Daniela Melillo (545973)
Simone Manocchio (6081062)
Antonella Angiolillo (2795587)
Paola Migliorini (361490)
Diana Boraschi (5088)
Emilia Vitale (271466)
Alfonso Costanzo (6081065)

December 2018

Results of multiple linear regression models without control for confounding variables. Values are β...

Additional file 1: of Systemic infection modifies the neuroinflammatory response in late stage Alzheimer’s disease

Sonja Rakic (5729885)
Yat Hung (5729888)
Matthew Smith (326340)
Denise So (5729891)
Hannah Tayler (5729894)
William Varney (5729897)
Joe Wild (5729900)
Scott Harris (306518)
Clive Holmes (237359)
Seth Love (122101)
William Stewart (28871)
James Nicoll (4733223)
Delphine Boche (458992)

September 2018

Table S1. Characteristics of the primary antibodies, immunohistochemistry conditions and expression ...

Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâs disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Femminella (6553430)
Eleni Frangou (6553433)
Sharon Love (6245381)
Gail Busza (6553436)
Clive Holmes (237359)
Craig Ritchie (3531092)
Robert Lawrence (229647)
Brady McFarlane (6553439)
George Tadros (6553442)
Basil Ridha (6553445)
Carol Bannister (6553448)
Zuzana Walker (573075)
Hilary Archer (6553451)
Elizabeth Coulthard (6553454)
Ben Underwood (6553457)
Aparna Prasanna (6553460)
Paul Koranteng (6553463)
Salman Karim (6553466)
Kehinde Junaid (6553469)
Bernadette McGuinness (237354)
Ramin Nilforooshan (5172128)
Ajay Macharouthu (6553472)
Andrew Donaldson (6553475)
Simon Thacker (6553478)
Gregor Russell (6553481)
Naghma Malik (6553484)
Vandana Mate (6553487)
Lucy Knight (6553490)
Sajeev Kshemendran (6553493)
John Harrison (3512513)
David Brooks (5369636)
Anthony Passmore (6553496)
Clive Ballard (89605)
Paul Edison (6398009)

April 2019

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb

Additional file 2: of Detection of tau in Gerstmann-StrĂ¤ussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET

Shannon Risacher (3578255)
Martin Farlow (229715)
Daniel Bateman (5907221)
Francine Epperson (5907224)
Eileen Tallman (5907227)
Rose Richardson (4102288)
Jill Murrell (281856)
Frederick Unverzagt (4837701)
Liana Apostolova (5907230)
Jose Bonnin (5907233)
Bernardino Ghetti (229719)
Andrew Saykin (3203685)

October 2018

Table S1. Regional [18F]Flortaucipir SUVR in PRNP F198S GSS Patients Relative to Early-Onset Alzheim...

Marie Boltz (5755031)
Ashley Kuzmik (5755034)
Barbara Resnick (5755037)
Rebecca Trotta (5755043)
Jacqueline Mogle (5755046)
Rhonda BeLue (4962424)
Douglas Leslie (5755049)
James Galvin (5755052)

September 2018

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist. (PDF 175...

Additional file 1: of Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimerâs disease: a network meta-analysis of 41 randomized controlled trials

Kai-Xin Dou (6161522)
Meng-Shan Tan (6161525)
Chen-Chen Tan (523854)
Xi-Peng Cao (5206148)
Xiao-He Hou (6161528)
Qi-Hao Guo (6161531)
Lan Tan (477054)
Vincent Mok (397930)
Jin-Tai Yu (477053)

December 2018

Supplementary 1. Network meta-analysis model. Supplementary 2. References for included trials. Suppl...

Additional file 1: of Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease

Hua Zhang (12549)
Kok Ng (5799602)
Joseph Therriault (5799605)
Min Kang (287002)
Tharick Pascoal (3581390)
Pedro Rosa-Neto (301841)
Serge Gauthier (301840)

September 2018

Table S1. Diagnostic accuracy of CSF P-tau, VILIP-1, and YKL-40 (Adjusted for age, gender, education...

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease in two global, randomized, phase 3 trials

Rik Vandenberghe (674079)
Juha Rinne (3429236)
MercĂ¨ Boada (3429254)
Sadao Katayama (3429221)
Philip Scheltens (142045)
Bruno Vellas (133953)
Michael Tuchman (3429227)
Achim Gass (539278)
Jochen Fiebach (3429218)
Derek Hill (3429203)
Kasia Lobello (3429245)
David Li (194538)
Tom McRae (3429230)
Prisca Lucas (3429212)
Iona Evans (3429239)
Kevin Booth (3429224)
Gerald Luscan (3429209)
Bradley Wyman (3429233)
Lisa Hua (3429251)
Lingfeng Yang (3429206)
H. Brashear (3429248)
Ronald Black (3429215)

May 2016

Inclusion and exclusion criteria. Inclusion and exclusion criteria, similar to those used in the 301...

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S1. SUVR longitudinal analysis. SUVR at week 69 compared to SUVR at baseline using different ...

Additional file 1: of Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Antonella Tramutola (284818)
Chiara Lanzillotta (5933198)
Eugenio Barone (297203)
Andrea Arena (5933201)
Ilaria Zuliani (5933204)
Luciana Mosca (83281)
Carla Blarzino (328306)
D. Butterfield (5933210)
Marzia Perluigi (297205)
Fabio Di Domenico (328312)

November 2018

List of antibodies used for WB and IF analysis. For each antibody employed in the study is reported ...

Additional file 1: of Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

Steinunn Thordardottir (5205731)
Elena Rodriguez-Vieitez (5205734)
Ove Almkvist (3463091)
Daniel Ferreira (4515394)
Laure Saint-Aubert (3463088)
Anne Kinhult-Ståhlbom (5205737)
Håkan Thonberg (6730)
Michael Schöll (4742400)
Eric Westman (24165)
Anders Wall (3115698)
Maria Eriksdotter (693854)
Henrik Zetterberg (144718)
Kaj Blennow (58615)
Agneta Nordberg (234998)
Caroline Graff (281203)

May 2018

Longitudinal z-scores for the RAVL total learning test measuring episodic memory in brothers A and B...

Marielle Delnomdedieu (434291)
Sridhar Duvvuri (3491186)
David Li (194538)
Nazem Atassi (3491174)
Ming Lu (122276)
H. Brashear (3429248)
Enchi Liu (3491183)
Seth Ness (3491177)
James Kupiec (3491180)

March 2016

List of investigators and corresponding ethics committees or institutional review boards. (DOC 60 kb

Additional file 1: of Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression?

Paola Italiani (519267)
Ilaria Puxeddu (303574)
Sabrina Napoletano (6081056)
Emanuele Scala (6081059)
Daniela Melillo (545973)
Simone Manocchio (6081062)
Antonella Angiolillo (2795587)
Paola Migliorini (361490)
Diana Boraschi (5088)
Emilia Vitale (271466)
Alfonso Costanzo (6081065)

December 2018

Results of multiple linear regression models without control for confounding variables. Values are β...

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Abstract

Extracted data

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Abstract

Extracted data

Related items

Related items

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Abstract

Extracted data

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Abstract

Extracted data

Related items

Related items

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease